Major coagulation disorders and parameters in COVID-19 patients

European Journal of Medical Research

Mahshid Taheri Khameneh¹  Elahe Mahmoodi Khaledi²  Azadeh Teimury² 

[1] Center of Excellence for Biodiversity, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran;Department of Cell and Molecular Biology, University of Kashan, Kashan, Iran;

关键词: Anticoagulant therapies;    Coagulation parameters;    Coagulopathy;    COVID-19;    Thromboembolic events;   

DOI  :  10.1186/s40001-022-00655-6

来源: Springer

【 摘 要 】

Coronavirus disease 2019 (COVID-19), with a high prevalence rate, has rapidly infected millions of people around the world. Since viral infections can disrupt the coagulation and homeostasis cascades, various inflammatory and coagulation problems occur due to COVID-19 infection, similar to coronavirus epidemics in 2003 and 2004. According to multiple previous studies, in the present research, we reviewed the most commonly reported problems of COVID-19 patients, such as venous thromboembolism, pulmonary embolism, disseminated intravascular coagulation, etc. and investigated the causes in these patients. Coagulation and inflammatory markers, such as platelets and fibrinogen, C-reactive protein, lactate dehydrogenase, d-dimer, prothrombin time, etc., were also discussed, and the treatment options were briefly reviewed. In addition to coagulation treatments, regular examination of coagulation parameters and thrombotic complications can be helpful in the timely treatment of patients. Therefore, it is helpful to review the coagulation problems in COVID-19 patients. Although all mentioned problems and markers are important in COVID-19, some of them are more valuable in terms of diagnosis and prognosis.

【 授权许可】

CC BY